Since Rich first profiled Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQB:BABYF), the stock has doubled in value. Anyone who invested on Rich’s initial recommendation has seen shares climb from $0.34 a pop to $0.70.
One of the reasons this stock continues to rally is that Else routinely announces exciting news. As the company approaches the launch of its patented, 100% plant-based infant formula, it has more news to tout today.
“Else Nutrition reminds me of Tesla—it’s another company that’s changing the world,” says Rich. “This is one of the biggest plays for our community, and they’ve got more breaking news.”
Else Signs Production MOU with Leading Organic Baby Formula Producer
On February 4, Else Nutrition announced that it signed a 5-year production Memorandum of Understanding (MOU) with a leading US-based organic baby formula producer.
As a result of the MOU, the company will operate a State-Of-The-Art Infant Nutrition Facility. At this facility, it will produce its proprietary powder for infant, toddler formula and children’s nutritional drinks.
The company will also invest in a dedicated packaging and manufacturing line for its products. It will invest C$500,000 to bring this to fruition.
Else Nutrition CEO Hamutal Yitzhak said of the deal:
“After a rigorous selection process, we are delighted to enter into this production MOU, as it will allow us to ensure the highest quality and purity standards for Else formula. This world-class facility provides for hands-on monitoring of each batch, ensuring increased testing accuracy and the highest quality in finished products. Having such high-caliber, long-term production in the U.S. ensures we can efficiently meet future demand in this key global market while adhering to our strict quality standards.”
Else Nutrition’s first products will launch in the US in Q2 2020. This will be its plant-based, non-dairy, non-soy toddler formula and children’s nutritional drinks.
“This launch is right around the corner,” explains Rich. “We haven’t even started doing sales yet! What do you think is going to happen when they start sales? I predict BABY goes to $1.00.”
Else Nutrition’s Strong Patents and Expanding Portfolio
Else enjoys very strong IP protection. This will allow it to fully capitalize on being the first mover in the plant-based infant formula space.
BABY’s formula has received patents in 20 countries, including the United States, Australia, Japan, Ukraine, Israel, Russia, South Africa, and New Zealand. The company also has a further 50+ patents pending.
Two weeks ago, Else received a notice of allowance from the US Patent Office to extend its existing patents to cover the adult market for malnutrition.
This means the company’s proprietary formula can be marketed to adults who have specific malnutrition-related conditions. Conditions like this include lean body mass and declining basal metabolic rates.
Else is ready to disrupt the plant-based foods market. Data from the Plant Based Foods Association and The Good Food Institute reveals that sales of plant-based foods grew 11 percent across America last year. The US market for 2019 is valued at $4.5 billion and is likely to continue to grow at a similar rate.
What do you think of Else Nutrition? Will the plant-based trend be a game-changer for stocks like BABY? Let us know your thoughts!
Featured image: DepotsitPhotos © Komokvm